February 28, 2025

New Member: Welcome in our cluster to CAVIGEN UG

New Member: Welcome in our cluster to CAVIGEN UG
Go back

CAVIGEN develops thermoformed microstructures for cell culture, including microcavities, porous microcavities, sensor-integrated microcavities (sensor arrays), and microchannels. Its patented technology enables precise oxygen measurement in 3D cell cultures, enhancing the physiological relevance of in vitro models, improving drug development processes, and reducing the need for animal testing.

CAVIGEN’s business model follows a razor-and-blade approach, offering a measurement device alongside disposable sensor arrays for organoid generation and analysis. In addition, the company provides custom development services to integrate its microstructures into existing systems.

Target customers include pharmaceutical companies, CROs, biotech firms, and organ-on-chip manufacturers developing advanced in vitro models. Currently preparing for market entry, CAVIGEN is testing its first prototypes with academic research groups and industry partners while actively seeking strategic partners and investors to accelerate adoption within the pharmaceutical sector.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Study shows how lymph node architecture affects cancer growth

Study shows how lymph node architecture affects cancer growth

A new study maps the organisation of immune and stromal cells in lymph nodes and shows how loss of this organisation affects prognosis in certain lymphomas Summary Researchers from EMBL Heidelberg, Heinrich Heine University Düsseldorf (HHU), and Düsseldorf University Hospital (UKD) have succeeded for the first time in mapping the organisation of immune and stromal […]

read more
High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

Meningiomas are the most common brain tumors. Until now, only two methods have generally been considered for treating them: surgery and radiation therapy. A research team in Heidelberg has now developed a potential new approach for effective systemic therapy. Its members from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital (UKHD) tested the effectiveness […]

read more
Development of a method for improved monitoring of the early stages of bone marrow cancer

Development of a method for improved monitoring of the early stages of bone marrow cancer

An international team, including researchers from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital, has developed the PANGEA-SMM prognostic tool. This tool makes it possible to determine with greater accuracy than before whether a precancerous condition—known as “smoldering multiple myeloma”—is progressing and thus requires treatment. The free online tool for treatment teams is available […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp